ACCURAY INC
About ACCURAY INC
Accuray Inc is a radiation oncology company that develops, manufactures, sells and supports precise, treatment solutions which set the standard of radiation therapy care with the objective of helping patients live lives. The company's technology, The CyberKnife, is used to treat multiple types of cancer and tumors throughout the body. The CyberKnife Systems automatically track, detect and correct for a tumor and patient movement in real-time during the procedure, enabling delivery of precise, high dose radiation with sub-millimetre accuracy while patients breathe normally, without manual user intervention.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $458.5M
- Net income
- -$1.6M
- Total assets
- $470.2M
- Market cap
- $40.7M
- Gross margin
- 32.1%
- Operating margin
- 1.7%
- Net margin
- -0.3%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $458.5M
- Cost of revenue
- $311.5M
- Gross profit
- $147.0M
- Operating expenses
- $139.1M
- Operating income
- $7.8M
- Income tax
- $2.7M
- Net income
- -$1.6M
- EPS (basic)
- $-0.02
- EPS (diluted)
- $-0.02
Balance sheet
- Total assets
- $470.2M
- Current assets
- $317.5M
- Total liabilities
- $389.1M
- Current liabilities
- $192.6M
- Shareholders’ equity
- $81.2M
Cash flow
- Operating cash flow
- $2.9M
- Investing cash flow
- -$8.5M
- Financing cash flow
- -$4.3M
- Net cash flow
- -$8.3M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $40.7M
- EPS (diluted)
- $-0.02
- Shares outstanding
- 116.2M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Feb 8, 2007
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $1.6M in FY2025.
- Revenue grew 16% from FY2021 to FY2025.
- Gross margin of 32.1%, net margin -0.3%.
- Trading 81% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review ACCURAY INC.
Write a review
News about ACCURAY INC
News & sentiment via Polygon.io
